Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
770 results about "Gastrointestinal disorder" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Method and system for vagal blocking and/or vagal stimulation to provide therapy for obesity and other gastrointestinal disorders
InactiveUS20050137644A1Eliminates repeated surgeryOvercomes shortcomingElectrotherapyArtificial respirationDiseaseDisease irritable bowel
Method and system to provide therapy for obesity and gastrointestinal disorders such as FGIDs, gastroparesis, gastro-esophageal reflex disease (GERD), pancreatitis and ileus comprises vagal blocking and / or vagal stimulation. Vagal blocking may be in the afferent or efferent direction, and may be with or without stimulation pulses. Blocking may be provided by one of a number of different electrical blocking techniques. Electrical signals may be provided with an external stimulator in conjunction with an implanted stimulus-receiver, or an implanted stimulus-receiver comprising a high value capacitor for temporary power source. In one embodiment, the external stimulator may comprise an optional telemetry unit. The addition of the telemetry unit to the external stimulator provides the ability to remotely interrogate and change stimulation programs over a wide area network, as well as other networking capabilities,
Owner:NEURO & CARDIAC TECH
Enteric rhythm management
InactiveUS20040176812A1Function increaseAltered autonomic balanceSpinal electrodesImplantable neurostimulatorsBlocking nerveNerve impulse
Owner:RESHAPE LIFESCIENCES INC
Methods for treating gastrointestinal disorders
A small implantable stimulator(s) having at least two electrodes is implanted adjacent to a gastrointestinal nerve and / or muscle for the stimulation treatment of gastrointestinal disorders, including gastrointestinal motility, sphincteric disorders, and / or eating disorders. The stimulator provides a means of stimulating tissue at a stimulation site when desired, and may be implanted via a minimal surgical procedure.
Owner:BOSTON SCI NEUROMODULATION CORP
Method of treating gastrointestinal diseases associated with species of genus clostridium
The invention includes a method of treating gastrointestinal diseases associated with species of genus Clostridium such as clostridium deficit in human patients with gastrointestinal disorders having an etiological component such as a microbial agent producing a toxin where treated with an antimicrobial composition an amount effective to inhibit or eliminate the microbial agent. The antimicrobial composition in a form of probiotic mixture can be administrated alone or in combination with an antimicrobial agent, such as a bacteriophage which is specific for a bacterium producing toxin or antibiotics which are then used to eliminate or inhibit the clostridial species overgrown in a patient's gastrointestinal tract. Disorders that can be treated by the method of the invention include diarrhea or inflammatory bowel diseases such as colitis or Crohn's disease.
Owner:UNITED STATES OF AMERICA
Method of using spinal cord stimulation to treat gastrointestinal and/or eating disorders or conditions
ActiveUS20060074456A1Enhance gastric motilityIncreasing) gastric motilityElectrotherapyDiseaseMedicine
The present invention involves a method and a system for using electrical stimulation to treat gastrointestinal and / or eating disorders. More particularly, the method comprises surgically implanting an electrical stimulation lead that is in communication with predetermined thoracic vertebral segments to cause spinal nervous tissue stimulation, thus treating a wide variety of gastrointestinal disorders.
Owner:ADVANCED NEUROMODULATION SYST INC
Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and / or a P2X2 / 3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
Owner:ROCHE PALO ALTO LLC
Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
Owner:HOPITAL SAINTE JUSTINE
Floating, multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
ActiveUS20130345519A1Expand the treatment spaceHelp positioningStentsBalloon catheterLess invasive surgeryGastrointestinal disorder
Improved methods and devices for performing an endoscopic surgery are provided. Systems are taught for operatively treating gastrointestinal disorders endoscopically in a stable, yet dynamic operative environment, and in a minimally-invasive manner. Such systems include, for example, an endoscopic surgical suite. The surgical suite can have a reversibly-expandable retractor that expands to provide a stable, operative environment within a subject. The expansion can be asymmetric around a stabilizer subsystem to maximize space for a tool and an endoscope to each be maneuvered independently to visualize a target tissue and treat the target tissue from outside the patient in a minimally invasive manner.
Owner:BOSTON SCI SCIMED INC
Transcutaneous electrical nerve stimulator for appetite control
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Methods for treating gastrointestinal disorders
InactiveUS20110097401A1Suitable for treatmentSalicyclic acid active ingredientsBiocideGastrointestinal disorderGastrointestinal tract
Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus.
Owner:MERITAGE PHARMA INC
Treatment of gastrointestinal disorders
The present invention relates to the use of a therapeutic or nutraceutical composition for the treatment of a gastrointestinal disorder, namely ulcerative colitis. In addition, the present invention provides methods of treating subjects suffering from gastrointestinal disorders such as ulcerative colitis.
Owner:UNIV COURT OF THE UNIV OF DUNDEE
Transcutaneous electrical nerve stimulator for appetite control
ActiveUS20050075678A1Appetite suppressantInducing feeling of satietyElectrotherapyArtificial respirationDiseaseGastrointestinal disorder
A method for the treatment of eating and gastrointestinal disorders through transcutaneous electrical nerve stimulation of the sympathetic celiac ganglia and nerve pathways innervating the stomach.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
InactiveUS6685971B2Restore physiological structure and functionPromote general health of whole bodyBiocideAerosol deliveryDiseaseAdditive ingredient
The present invention provides novel compositions and methods for protecting and promoting cell growth and restoring physiological structure and function to mucosal tissue of the body, especially mucosa in the gastrointestinal tract. The composition can be used as a pharmaceutical or nutraceutical to treat a gastrointestinal disorder or to promote general health of an animal, preferably a human. The composition is in an oral dosage form and comprises edible oil homogenized with a sterol compound at a concentration of at least 0.5% by weight and edible wax at a concentration ranging from 3% to 30% by weight. The composition can also be used to deliver other active ingredients to the gastrointestinal tract for treating various diseases.
Owner:XU RONGXIANG
Synbiotics
InactiveUS20060093592A1Enhance immune functionImprove Gut HealthAntibacterial agentsBiocideIntestinal structureSynbiotics
A novel product comprising a mixture of probiotic and prebiotic ingredients for the treatment of IBS, IBD, Crohn's disease, antibiotic induced diarrhea and other bowel disorders is described herein. Stabilized rice bran derivatives, including stabilized rice bran, RiSolubles, RiceMucil, and Cea100, are used as the source of prebiotics. The prebiotic source is not only rich in fructo-oligosaccharides, but also has potent antioxidants and phytonutrients for intestinal health and the proliferation of bifido-bacteria in the intestines. The probiotics used are different combinations and concentrations of Lactobacilli species, depending on the specific gastrointestinal disease which is targeted. When refrigerated, the products are shelf-stable (95-99%) for at least one year.
Owner:NUTRACEA
Method and compositions for the treatment of gastrointestinal disorders
ActiveUS20060094658A1Reduce accumulationIncrease gastrointestinal motilityPeptide/protein ingredientsMetabolism disorderGastroparesisInflammatory Bowel Diseases
Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
Owner:IRONWOOD PHARMA
Macrocyclic ghrelin receptor modulators and methods of using the same
ActiveUS20080194672A1Reduced and dysfunctional gastrointestinal motilityInhibit gastrointestinal motilityAntibacterial agentsOrganic active ingredientsSomatotropic hormonePharmaceutical Substances
The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and / or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
Owner:OCERA THERAPEUTICS INC
Fused bicyclic or tricyclic amino acids
Owner:PFIZER INC
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ActiveUS20090048175A1Maintain good propertiesIncrease resistanceOrganic active ingredientsSenses disorderPhosphodiesteraseGastrointestinal cancer
The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
Owner:BAUSCH HEALTH IRELAND LTD
A2B adenosine receptor antagonists
InactiveUS6977300B2Avoid actionMaintain liquidityBiocideNervous disorderMedicineGastrointestinal disorder
Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
Owner:GILEAD SCI INC
Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
ActiveUS20130274553A1Expand the treatment spaceHelp positioningBalloon catheterCannulasGastrointestinal disorderEndoscopic surgery
Improved methods and devices for performing an endoscopic surgery are provided. Systems are taught for operatively treating gastrointestinal disorders endoscopically in a stable, yet dynamic operative environment, and in a minimally-invasive manner. Such systems include, for example, an endoscopic surgical suite. The surgical suite can have a reversibly-expandable retractor that expands to provide a stable, operative environment within a subject. The expansion can be asymmetric around a stabilizer subsystem to maximize space for a tool and an endoscope to each be maneuvered independently to visualize a target tissue and treat the target tissue from outside the patient in a minimally invasive manner.
Owner:BOSTON SCI SCIMED INC
Methods and compositions for the treatment of gastrointestinal disorders
InactiveUS20070010450A1Increase gastrointestinal motilityReduce inflammationPeptide/protein ingredientsMetabolism disorderIntestinal tract diseasesGastroparesis
Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
Owner:IRONWOOD PHARMA
Selective opioid compounds
ActiveUS20090209569A1Reducing lipid permeability of drugReduce penetrationAntibacterial agentsBiocideDiseaseInterstitial cystitis
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which relates to morphinan compounds useful as μ, δ, and / or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
Owner:ALKERMES INC
Autonomic nerve stimulation to treat a gastrointestinal disorder
A method and apparatus for stimulating a portion of a vagus nerve of a patient to treat a gastrointestinal disorder is provided. At least one electrode is coupled to at least one portion of a vagus nerve of the patient. The portion of the a vagus nerve may include an esophageal plexus, a myenteric plexus of aurbach, a submucous plexus of the meissner, a principal nerve of the lesser curvature of the stomach, and a gastric branch of said vagus nerve. An electrical signal is applied to the portion of the vagus nerve using the electrode to treat the gastrointestinal disorder.
Owner:LIVANOVA USA INC
Macrocyclic modulators of the ghrelin receptor
ActiveUS20060025566A1Promote gastrointestinal motilityModulating activity of receptorDigestive systemCyclic peptide ingredientsInflammationCentral nervous system
Owner:OCERA THERAPEUTICS INC
Methods for prevention and treatment of gastrointestinal disorders
InactiveUS20050004222A1High activityPrevent and reduce severity of and symptomBiocidePeptide/protein ingredientsGastrointestinal disorderHuman patient
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Vibrator pill for gastrointestinal disorders
A vibrating pill is disclosed capable of stimulating the gastrointestinal tract to induce gastrointestinal contractions and peristalsis, as well as other functions within the gastrointestinal tract.
Owner:AMIRANA OMAR
Agonists of Guanylate Cyclase UseFul For The Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
ActiveUS20100093635A1Reduce inflammationPositive therapeutic effectAntipyreticAnalgesicsPhosphodiesteraseGastrointestinal cancer
The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
Owner:BAUSCH HEALTH IRELAND LTD
Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
ActiveUS20100284972A1Beneficial effect on of subjectGood for healthOrganic active ingredientsBiocideDiabetes mellitusMedicine
Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.
Owner:TATE & LYLE INGREDIENTS FRANCE
Method for treating cachexia with retinoid ligands
InactiveUS20070185055A1BiocideSilicon compound active ingredientsRetinoidObstructive Pulmonary Diseases
The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.
Owner:JIANG GUANG LIANG +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com